Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $3.00 price target on the stock.
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million [Yahoo! Finance]
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
PacBio Grants Equity Incentive Award to New Employee
Jim Gibson to join PacBio as Chief Financial Officer